Relevance of the Daily Dose of Imatinib Mesylate (IM) Rather Than Its Trough Plasma Concentration for Achieving Deep Molecular Response in Patients with Chronic Myeloid Leukemia.
暂无分享，去创建一个
Y. Hasegawa | H. Kojima | K. Suzukawa | Takayoshi Ito | S. Chiba | H. Mukai | C. Yoshida | T. Komeno | Masami Fujii | D. Kudo | S. Shimizu | Y. Okoshi | M. Hori | M. Kamoshita | A. Shinagawa | N. Watanabe | N. Chikatsu | Yuriko Monma | Tomofumi Kimura